Advertisement

GI & Endoscopy

Advertisement

Allergan's board of directors authorized the company to buy back $2 billion in stock, while also committing to increasing its quarterly dividends and reaffirming its decision to pay down $3.75 billion in debt by 2018.

Advertisement